Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Precigen, Inc. (NASDAQ:PGEN) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.00.

Several research firms recently commented on PGEN. StockNews.com upgraded shares of Precigen to a “sell” rating in a report on Thursday, August 1st. JMP Securities cut their price target on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, August 15th. Finally, HC Wainwright reduced their target price on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th.

Insider Transactions at Precigen

In other news, SVP Jeffrey Thomas Perez bought 58,823 shares of Precigen stock in a transaction dated Friday, August 9th. The shares were acquired at an average cost of $0.85 per share, with a total value of $49,999.55. Following the completion of the transaction, the senior vice president now owns 743,097 shares in the company, valued at approximately $631,632.45. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 44.90% of the company’s stock.

Institutional Trading of Precigen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. EntryPoint Capital LLC bought a new stake in shares of Precigen in the first quarter worth $31,000. Traphagen Investment Advisors LLC bought a new stake in shares of Precigen in the third quarter worth $29,000. SG Americas Securities LLC increased its stake in Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 13,823 shares during the last quarter. AQR Capital Management LLC increased its stake in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 18,097 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 25,681 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Stock Performance

NASDAQ PGEN opened at $0.82 on Wednesday. Precigen has a one year low of $0.79 and a one year high of $1.93. The company’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.27. The firm has a market capitalization of $208.07 million, a price-to-earnings ratio of -1.52 and a beta of 1.68.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative net margin of 3,084.55% and a negative return on equity of 90.99%. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Sell-side analysts forecast that Precigen will post -0.44 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.